Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

CardioDx completes multicenter validation study for Corus CAD

CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus CAD, the first and only gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain.

26 Aug 2009

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Karolinska University Hospital in Solna, Stockholm, Sweden.

24 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

MedAssurant announces certification of event rate outcomes for HIP Medicare Advantage patients

MedAssurant, Inc., a leading provider of data-driven healthcare solutions, announced today that the Disease Management Purchasing Consortium (DMPC) has certified the event rate outcomes for HIP Health Plan of New York (HIP) Medicare Advantage patients.

21 Aug 2009

HeartWare achieves enrollment milestone under its ADVANCE Clinical Trial in the U.S

HeartWare International, Inc. (Nasdaq: HTWR - ASX: HIN) today announced that HeartWare has surpassed 50 implants in the United States under its ADVANCE Clinical Trial, marking an important early enrollment milestone.

21 Aug 2009

FDA permits Worldheart for bridge-to-transplant study of the Levacor Ventricular Assist Device

World Heart Corporation (WorldHeart) - (Nasdaq: WHRT) announced today that it has received FDA conditional approval to begin a bridge-to-transplant (BTT) study of the Levacor Ventricular Assist Device (VAD) at ten US centers.

21 Aug 2009

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population-based cohort study

Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on bmj.com today.

20 Aug 2009

Newly discovered anti-aging gene linked to high blood pressure

Researchers at the University of Oklahoma Health Sciences Center have shown the first link between a newly discovered anti-aging gene and high blood pressure. The results, which appear this month in the journal Hypertension, offer new clues on how we age and how we might live longer.

19 Aug 2009

Medicare picks twelve New Jersey hospitals to test incentive system

Twelve New Jersey hospitals and their participating physicians have received approval from the federal government to test an innovative new incentive method that aims to reduce healthcare costs while improving quality of care.

19 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

FDA places Geron Corporation's IND for spinal cord injury on clinical hold

Geron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.

19 Aug 2009

Texas Heart Institute receives $4.1 million to determine the effect of pulseless blood flow on bodily functions

The National Institutes of Health (NIH) has awarded a $4.1 million grant to the Texas Heart Institute at St. Luke’s Episcopal Hospital (THI at SLEH) to determine the effect of pulseless blood flow on bodily functions. This knowledge will be used in the development of a total artificial heart (TAH) that produces continuous, pulseless blood flow.

18 Aug 2009

Response Biomedical announces Q2 2009 financials

Response Biomedical Corporation (TSX:RBM) (OTCBB:RPBIF) reported that clinical products revenue for the three and six month periods ended June 30, 2009 increased 373% and 208% to $1,805,308 and $3,548,014, respectively, compared to $381,615 and $1,150,760 for the same periods in 2008.

13 Aug 2009

New nutrition practice guidelines for patients with spinal cord injury

The American Dietetic Association has published new evidence-based nutrition practice guidelines for registered dietitians on nutrition care for patients with spinal cord injury.

12 Aug 2009

High-fat diets just as unhealthy in short term as long term

Short-term memory getting worse? Exercise getting harder? Examine your diet. New research published online in The FASEB Journal showed that in less than 10 days of eating a high-fat diet, rats had a decreased ability to exercise and experienced significant short-term memory loss. These results show an important link between what we eat, how we think, and how our bodies perform.

12 Aug 2009

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.

12 Aug 2009

High-fat diet affects physical and memory abilities of rats after 9 days

Rats fed a high-fat diet show a stark reduction in their physical endurance and a decline in their cognitive ability after just nine days, a study by Oxford University researchers has shown.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Fainting may point to more serious, underlying cardiovascular condition

For those who suffer from fainting spells, the mysterious episodes can be quite scary. Far too often, fainting is chalked up to stress or other mental health issues. However, medical experts at Rush University Medical Center say that reoccurring fainting spells, also known as syncope, could be an important symptom that can point to a more serious, underlying cardiovascular condition.

10 Aug 2009

Heart Failure News and Research

Further Reading

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

CardioDx completes multicenter validation study for Corus CAD

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

MedAssurant announces certification of event rate outcomes for HIP Medicare Advantage patients

HeartWare achieves enrollment milestone under its ADVANCE Clinical Trial in the U.S

FDA permits Worldheart for bridge-to-transplant study of the Levacor Ventricular Assist Device

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population-based cohort study

Newly discovered anti-aging gene linked to high blood pressure

Medicare picks twelve New Jersey hospitals to test incentive system

Bioheart's executive management team strengthened by the inclusion of board members

FDA places Geron Corporation's IND for spinal cord injury on clinical hold

Texas Heart Institute receives $4.1 million to determine the effect of pulseless blood flow on bodily functions

Response Biomedical announces Q2 2009 financials

New nutrition practice guidelines for patients with spinal cord injury

High-fat diets just as unhealthy in short term as long term

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

High-fat diet affects physical and memory abilities of rats after 9 days

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Fainting may point to more serious, underlying cardiovascular condition

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News